VKTX – Viking Therapeutics, Inc.
Float Short %
22.19
Margin Of Safety %
Put/Call OI Ratio
0.27
EPS Next Q Diff
-0.13
EPS Last/This Y
-1.6
EPS This/Next Y
-1.11
Price
34.08
Target Price
93.39
Analyst Recom
1.11
Performance Q
3.37
Relative Volume
0.86
Beta
0.76
Ticker: VKTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | VKTX | 37.21 | 0.24 | 0.15 | 254790 |
| 2025-12-29 | VKTX | 36.47 | 0.23 | 0.31 | 240273 |
| 2025-12-30 | VKTX | 35.33 | 0.24 | 0.38 | 242674 |
| 2025-12-31 | VKTX | 35.14 | 0.24 | 0.17 | 246336 |
| 2026-01-02 | VKTX | 35.43 | 0.24 | 0.23 | 247958 |
| 2026-01-05 | VKTX | 32.13 | 0.24 | 0.23 | 238221 |
| 2026-01-06 | VKTX | 32.28 | 0.24 | 0.22 | 247708 |
| 2026-01-07 | VKTX | 32.38 | 0.24 | 0.25 | 250189 |
| 2026-01-08 | VKTX | 31.63 | 0.25 | 0.15 | 255684 |
| 2026-01-09 | VKTX | 31.96 | 0.24 | 0.32 | 258984 |
| 2026-01-12 | VKTX | 31.7 | 0.24 | 0.33 | 251941 |
| 2026-01-13 | VKTX | 30.68 | 0.24 | 0.29 | 260655 |
| 2026-01-14 | VKTX | 34.34 | 0.25 | 0.33 | 271340 |
| 2026-01-15 | VKTX | 31.96 | 0.24 | 0.41 | 287871 |
| 2026-01-16 | VKTX | 33.92 | 0.25 | 0.35 | 291374 |
| 2026-01-20 | VKTX | 33.51 | 0.25 | 0.26 | 156291 |
| 2026-01-21 | VKTX | 33.39 | 0.26 | 0.20 | 161848 |
| 2026-01-22 | VKTX | 34.08 | 0.27 | 0.26 | 164193 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | VKTX | 37.19 | -180.3 | - | -2.61 |
| 2025-12-29 | VKTX | 36.47 | -180.3 | - | -2.61 |
| 2025-12-30 | VKTX | 35.32 | -180.3 | - | -2.61 |
| 2025-12-31 | VKTX | 35.18 | -180.3 | - | -2.61 |
| 2026-01-02 | VKTX | 35.42 | -180.3 | - | -2.61 |
| 2026-01-05 | VKTX | 32.13 | -180.3 | - | -2.61 |
| 2026-01-06 | VKTX | 32.28 | -180.3 | - | -2.61 |
| 2026-01-07 | VKTX | 32.40 | -180.3 | - | -2.61 |
| 2026-01-08 | VKTX | 31.68 | -180.3 | - | -2.61 |
| 2026-01-09 | VKTX | 31.99 | -180.3 | - | -2.61 |
| 2026-01-12 | VKTX | 31.74 | -180.3 | - | -2.61 |
| 2026-01-13 | VKTX | 30.67 | -181.2 | - | -2.61 |
| 2026-01-14 | VKTX | 34.34 | -181.2 | - | -2.61 |
| 2026-01-15 | VKTX | 31.86 | -181.2 | - | -2.61 |
| 2026-01-16 | VKTX | 33.90 | -181.2 | - | -2.61 |
| 2026-01-20 | VKTX | 33.53 | -181.2 | - | -2.61 |
| 2026-01-21 | VKTX | 33.39 | -181.2 | - | -2.61 |
| 2026-01-22 | VKTX | 34.08 | -181.2 | - | -2.61 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | VKTX | -4.39 | -3.18 | 21.88 |
| 2025-12-29 | VKTX | -4.39 | -3.18 | 21.88 |
| 2025-12-30 | VKTX | -4.39 | -3.18 | 21.88 |
| 2025-12-31 | VKTX | -4.39 | -3.18 | 21.88 |
| 2026-01-02 | VKTX | -4.39 | -3.18 | 21.88 |
| 2026-01-05 | VKTX | -3.36 | -3.19 | 21.88 |
| 2026-01-06 | VKTX | -12.95 | -3.19 | 21.88 |
| 2026-01-07 | VKTX | -12.95 | -3.19 | 21.88 |
| 2026-01-08 | VKTX | -12.95 | -3.19 | 21.88 |
| 2026-01-09 | VKTX | -12.95 | -3.19 | 21.88 |
| 2026-01-12 | VKTX | -13.08 | -3.21 | 21.90 |
| 2026-01-13 | VKTX | -12.49 | -3.21 | 22.19 |
| 2026-01-14 | VKTX | -12.49 | -3.21 | 22.19 |
| 2026-01-15 | VKTX | -12.49 | -3.21 | 22.19 |
| 2026-01-16 | VKTX | -12.49 | -3.21 | 22.19 |
| 2026-01-20 | VKTX | -12.49 | -3.39 | 22.19 |
| 2026-01-21 | VKTX | -12.49 | -3.39 | 22.19 |
| 2026-01-22 | VKTX | -12.49 | -3.39 | 22.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.81
Avg. EPS Est. Current Quarter
-0.9
Avg. EPS Est. Next Quarter
-0.94
Insider Transactions
-12.49
Institutional Transactions
-3.39
Beta
0.76
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
18
Sentiment Score
80
Actual DrawDown %
65.7
Max Drawdown 5-Year %
-78.9
Target Price
93.39
P/E
Forward P/E
PEG
P/S
P/B
5.38
P/Free Cash Flow
EPS
-2.12
Average EPS Est. Cur. Y
-2.61
EPS Next Y. (Est.)
-3.72
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.86
Return on Equity vs Sector %
-60.5
Return on Equity vs Industry %
-44.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Viking Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 50
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today
news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics, Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading